Published in Eur Urol on February 22, 2011
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol (2014) 2.26
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging (2011) 1.53
Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer (2013) 1.25
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget (2013) 1.07
Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate (2013) 1.06
Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. J Cancer (2015) 0.91
Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J Urol (2012) 0.86
A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer. Oncotarget (2015) 0.85
Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res (2014) 0.84
MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples. Biomed Res Int (2014) 0.83
Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results. Eur Radiol (2015) 0.83
Surgical learning curve for open radical prostatectomy: Is there an end to the learning curve? World J Urol (2015) 0.81
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol (2013) 0.80
Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biol Cell (2015) 0.80
Low detectable prostate specific antigen after radical prostatectomy--treat or watch? J Urol (2014) 0.79
Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature. Cureus (2015) 0.77
Impact of positive surgical margins and their locations after radical prostatectomy: comparison of biochemical recurrence according to risk stratification and surgical modality. World J Urol (2013) 0.77
Radiation Therapy after Radical Prostatectomy: Implications for Clinicians. Front Oncol (2016) 0.76
Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy. Oncotarget (2016) 0.76
Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. Prostate Cancer Prostatic Dis (2015) 0.76
Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome. Biomed Res Int (2015) 0.75
Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news? Eur Urol (2011) 0.75
Genetic variants of the CYP1B1 gene as predictors of biochemical recurrence after radical prostatectomy in localized prostate cancer patients. Medicine (Baltimore) (2016) 0.75
Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget (2016) 0.75
A Framework for Treatment Decision Making at Prostate Cancer Recurrence. Med Decis Making (2017) 0.75
Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence. Int J Clin Oncol (2014) 0.75
Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings. Eur Urol Focus (2016) 0.75
Comment on: "Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years". World J Urol (2015) 0.75
Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol (2017) 0.75
Weight change, obesity, and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer (2017) 0.75
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950-2002). Ann Surg (2005) 4.72
The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol (2008) 4.10
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol (2010) 3.08
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg (2002) 2.68
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int (2010) 2.51
Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol (2010) 2.45
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol (2008) 2.40
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet (2004) 2.31
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29
Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. Urology (2011) 2.26
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.22
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol (2007) 2.12
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol (2011) 2.11
Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol (2005) 2.10
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol (2009) 2.05
Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol (2010) 2.05
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol (2005) 2.01
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer (2009) 2.00
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int (2005) 2.00
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol (2010) 1.93
Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient. Urology (2009) 1.92
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Prevalence of renal artery and kidney abnormalities by computed tomography among healthy adults. Clin J Am Soc Nephrol (2010) 1.91
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Clinical characteristics of potential kidney donors with asymptomatic kidney stones. Nephrol Dial Transplant (2011) 1.87
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int (2012) 1.87
Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int (2013) 1.84
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol (2008) 1.83
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol (2002) 1.82
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol (2003) 1.81
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 1.80
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? BJU Int (2008) 1.79
Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. Am J Kidney Dis (2008) 1.77